Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Latest From Novan Inc.

Verrica Ready To Target Pediatric Dermatologists With First Molluscum Therapy

Anticipating a July approval of its cantharidin formulation, Verrica says it is poised to implement a buy-and-bill model for a clinician-administered product with an addressable market of 6 million.

Business Strategies Research and Development Strategies

J.P. Morgan Stockwatch: No Substitute For M&A

Stock market reaction to the first day’s news from the 38th J.P. Morgan Healthcare conference in San Francisco was negative, probably because expectations for a continuation of December’s bumper M&A bonanza were too high.

 

M & A Advisory Committees

Novan Still Hopeful But May Be Stranded After Phase III Molluscum Failure

Nitric oxide-releasing SB206 missed the primary endpoint in a pair of Phase III studies, but Novan hopes a third study and success on a secondary endpoint still can lead to filing for approval.

Clinical Trials Business Strategies

Finance Watch: Here Come The IPOs Again As Bellus Raises $70m And Vir Joins The Queue

Public Company Edition: Bellus launched the first biopharma IPO in the US since mid-July and Vir Biotechnology, run by former Biogen CEO George Scangos, wants to raise $100m. Also, Turning Point's $202.5m offering and Zafgen's strategic review.

Financing Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
      • Macromolecule
      • Topical Delivery
  • Therapeutic Areas
  • Dermatology
  • Infectious & Viral Diseases
  • Alias(es)
  • Novan Therapeutics Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Novan Inc.
  • Senior Management
  • G. Kelly Martin, CEO
    William Hodges, Interim CFO
    Nathan Stasko, PhD, Pres. & CSO
    Jeff N Hunter, EVP, CBO
    Kevin Barber, VP, Reg Affairs
    Brian Johnson, Chief Commercial Officer
    Paula Brown Stafford, Chief Dev. Officer
    Stanley Hollenbach, SVP, R&D
    Carri Geer, VP, Pharma Dev
    Tim O'Sullivan, VP, Intellectual Capital
  • Contact Info
  • Novan Inc.
    Phone: (919) 485-8080
    4105 Hopson Rd.
    Morrisville, NC 27560
    USA
UsernamePublicRestriction

Register